Clovis Oncology's rucaparib improved survival in ovarian cancer patients

HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices

Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.

May 17, 2024

Vol.50 No.20

By Jacquelyn Cobb

Conversation with The Cancer Letter

NCI’s Lisa McShane: We need to understand the implications of HRD assay discordance

Homologous recombination deficiency tests are available from multiple vendors, and every day they are used to determine whether patients stand to benefit from PARP inhibitors.

May 17, 2024

Vol.50 No.20

By Jacquelyn Cobb

Funding Opportunities

DoD Ovarian Cancer Research Program anticipated funding opportunities for FY24

The FY24 Defense Appropriations Act is anticipated to provide funding for the Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members, and all women impacted by this disease.

April 05, 2024

Vol.50 No.14

In Brief

Shelley Tworoger named head of oncological science, associate director for population science at OHSU Knight

Shelley Tworoger, an epidemiologist at Moffitt Cancer Center, was named to two roles at OHSU: head of the Division of Oncological Sciences in the School of Medicine, and associate director for population science at the Knight Cancer Institute.

October 27, 2023

Vol.49 No.40

Drugs & Targets

CHMP issues positive opinion for Rubraca as a first-line maintenance treatment for advanced ovarian cancer

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval a Type II variation for Rubraca (rucaparib), as a first-line maintenance treatment for all women with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy.

October 20, 2023

Vol.49 No.39

Clinical Roundup

USC researchers develop blood test with the potential to detect early-stage ovarian cancer

A study on human tissue and plasma led by researchers at USC Norris Comprehensive Cancer Center shows that their newly developed blood test, OvaPrint, may distinguish between cancerous and benign pelvic masses with up to 91% accuracy, surpassing other commercially available tests.

October 13, 2023

Vol.49 No.38

Clovis Oncology’s rucaparib improved survival in ovarian cancer patients

YOU MAY BE INTERESTED IN

HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices

NCI’s Lisa McShane: We need to understand the implications of HRD assay discordance

DoD Ovarian Cancer Research Program anticipated funding opportunities for FY24

Shelley Tworoger named head of oncological science, associate director for population science at OHSU Knight

CHMP issues positive opinion for Rubraca as a first-line maintenance treatment for advanced ovarian cancer

USC researchers develop blood test with the potential to detect early-stage ovarian cancer

Renew today!

Subscriber content

Login